Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2006.
Restated Financial Statements for Fiscal Year-End 2005 and for Quarters Ended September 30, 2004 through March 31, 2006. Conference Call Scheduled for November 10 at 11:00 ET, 8:00 PT EMERYVILLE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , a drug development company focused...

Hearts unfair to 50+ women.
Byline: MOUMITA DAS Women are more susceptible to stroke than men. Study says indifference to health main cause Fifty-year-old Sarmistha Banerjee was alone at home preparing dinner when she suddenly started feeling uneasy. Within minutes, she became unconscious. Unfortunately, nobody was there at...

APTA, Coalition Urge Congress to 'Stop the Therapy Cap'.
ALEXANDRIA, Va., Nov. 13 /PRNewswire/ -- In less than 50 days, 1 in 7 Medicare beneficiaries(1) will be subject to an arbitrary financial limit on outpatient rehabilitation services, or a "therapy cap," without Congressional action. The American Physical Therapy Association (APTA) and a coalition representing patients, health care providers,...

Micrus Endovascular to Webcast 2006 Annual Meeting of Stockholders.
SAN JOSE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Micrus Endovascular Corporation today announced that its annual meeting of stockholders will be broadcast live over the Internet on Tuesday, November 14, 2006 at 2:00 p.m. Eastern time (11:00 a.m. Pacific time). Those listening to the meeting via the live Internet broadcast...

Intensive Lipitor Therapy Reduced Heart Attack and Stroke By One-Third In Patients With Chronic Kidney Disease, New Analysis Shows.
* Patients with heart disease and chronic kidney disease who took intensive Lipitor therapy (80 mg) reduced their risk of heart attack and stroke by 32 percent compared with patients taking low-dose Lipitor (10 mg). * An estimated 20 million Americans and 50 million people worldwide have...

Six Northeast Ohio Technology Centers Receive $1M for Commercialization Projects.
CLEVELAND, Nov. 14 /PRNewswire/ -- NorTech, Northeast Ohio's leading technology based economic development organization, today announced the distribution of $1 million to support the commercialization of six projects from the Technology Leaders' Group. The projects are being funded by a grant awarded earlier this year from the Fund for...

Neurobiological Technologies, Inc. and Nordmark Complete GMP Snake Facility in Germany for Production of Viprinex(TM) (Ancrod).
EMERYVILLE, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced the completion of a snake facility in Moorrege, Germany, near Hamburg. The facility, owned and operated by NTI's partner, Nordmark Arzneimittel GmbH & Co. KG (Nordmark), houses snakes that will provide the venom used to produce...

54 Why some stroke victims don't make smarter decisions.
NEUROSCIENCE--Patients who have suffered stroke or head injuries often lose the ability to make smart choices. For instance, they will place repeated bets on a particular outcome, even when the odds of winning are obviously very low. In July a research team at Johns Hopkins University helped pinpoint why....

When the able need a cane.
Since the right half of the ageing brain has nothing 'left' in it and the left half is never 'right', Rampage thought it fit to brainstorm. While so much has been said about the afflictions of the coronary arteries which produce angina and heart attacks, the same afflictions of...

New Study Shows Clexane(R) / Lovenox(R) (Enoxaparin Sodium Injection) is More Effective Than Unfractionated Heparin (UFH) for Preventing the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke.
ORLANDO, Florida, December 12 /PRNewswire-FirstCall/ -- - The PREVAIL Study Showed That in Acute Ischemic Stroke Patients Treated With Clexane(R) / Lovenox(R), the Risk of Having a VTE was Lowered by a Significant 43% With no Significant Increase in Clinically Important Bleedings When Compared to UFH Sanofi-aventis...